Reported the first partnership of its kind with Wavelength Pharmaceuticals, owned by US investment firm SK Capital Partners
As part of the agreement, a first in the pharmaceutical industry, the companies will develop, manufacture and market cannabis-based active pharmaceutical ingredients (APIs) for the global pharmaceutical industry
PR Newswire
TEL AVIV, Israel, Aug. 16, 2021